Skip to main content

Biofrontera AG (0DOL.L)

London Stock Exchange Healthcare Medical - PharmaceuticalsView data quality →
38.2Poor

ValueMarkers Composite Index

Top 4%#42,844 of 44,707

DCF data not available

Piotroski
2/9
Weak
Beneish
-3.00
Low Risk
Altman
0.90
Distress
DCF Value
-
N/A
ROIC
-66.7%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Biofrontera AG (0DOL.L) — VMCI valuation read

Across 120 indicators, Biofrontera AG (0DOL.L) lands at VMCI 38/100. The Healthcare sector median is 50, so the 12-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 0DOL.L in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 0DOL.L trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 0.6x leaves covenant headroom for 0DOL.L on the trailing balance sheet.

0DOL.L fell 1.0% over the trailing 7 days, with a +6.8% read on a 30-day basis.

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

CEO: Pilar de la Huerta Martinez88 employeesDEwww.biofrontera.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 0DOL.L’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.